Abstract
Humans are exposed to countless foreign compounds, typically referred to as xenobiotics. These can include clinically used drugs, environmental pollutants, food additives, pesticides, herbicides and even natural plant compounds. Xenobiotics are metabolised primarily in the liver, but also in the gut and other organs, to derivatives that are more easily eliminated from the body. In some cases, however, a compound is converted to an electrophile that can cause cell toxicity and transformation leading to cancer. Among the most important xenobiotic-metabolising enzymes are the cytochromes P450 (P450s). These enzymes represent a superfamily of multiple forms that exhibit marked species differences in their expression and catalytic activities. To predict how humans will metabolise xenobiotics, including drugs, human liver extracts and recombinant P450s have been used. New humanised mouse models are being developed which will be of great value in the study of drug metabolism, pharmacokinetics and pharmacodynamics in vivo, and in carrying out human risk assessment of xenobiotics. Humanised mice expressing CYP2D6 and CYP3A4, two major drug-metabolising P450s, have revealed the feasibility of this approach.
MeSH Terms
Animals
Cytochrome P-450 CYP2D6/genetics,metabolism
Cytochrome P-450 CYP3A
Cytochrome P-450 Enzyme System/genetics,metabolism
Humans
Mice
Mice, Transgenic
Xenobiotics/metabolism
Chemicals
Xenobiotics
Cytochrome P-450 Enzyme System
CYP3A protein, human
Cytochrome P-450 CYP2D6
Cytochrome P-450 CYP3A
CYP3A4 protein, human
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Gonzalez Frank J
Laboratory of Metabolism, National Cancer Institute, Building 37, Room 3106B, Bethesda, MD 20892, USA. fjgonz@helix.nih.gov
References (29)
29 references, click to expand
-
Establishment of transgenic mice carrying human fetus-specific CYP3A7.
Arch Biochem Biophys. 1996 May 15;329(2):235-240
PMID: 8638957
-
Cytochromes P450 expression systems.
Annu Rev Pharmacol Toxicol. 1995;35:369-90
PMID: 7598499
-
Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes.
J Pharmacol Exp Ther. 1997 Sep;282(3):1435-41
PMID: 9316857
-
Activation of procarcinogens by human cytochrome P450 enzymes.
Mutat Res. 1998 May 25;400(1-2):201-13
PMID: 9685642
-
The use of heterologously expressed drug metabolizing enzymes--state of the art and prospects for the future.
Pharmacol Ther. 1999 Nov;84(2):121-31
PMID: 10596902
-
Pharmacogenetics of sulfotransferase.
Annu Rev Pharmacol Toxicol. 2000;40:159-76
PMID: 10836131
-
Epoxide hydrolases: biochemistry and molecular biology.
Chem Biol Interact. 2000 Dec 1;129(1-2):41-59
PMID: 11154734
-
NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms.
Chem Biol Interact. 2000 Dec 1;129(1-2):77-97
PMID: 11154736
-
Genetic polymorphism and cancer risk.
Curr Oncol Rep. 2000 May;2(3):251-6
PMID: 11122850
-
Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis.
Mol Cell Biol. 2001 Feb;21(4):1393-403
PMID: 11158324
-
UDP-glucuronosyltransferases.
Curr Drug Metab. 2000 Sep;1(2):143-61
PMID: 11465080
-
Glutathione-S-transferase family of enzymes.
Mutat Res. 2001 Oct 1;482(1-2):21-6
PMID: 11535245
-
The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse.
Mol Pharmacol. 2001 Dec;60(6):1260-7
PMID: 11723233
-
Efficient Cre-loxP-induced mitotic recombination in mouse embryonic stem cells.
Nat Genet. 2002 Jan;30(1):66-72
PMID: 11740496
-
Cre/loxP recombination system and gene targeting.
Methods Mol Biol. 2002;180:175-204
PMID: 11873650
-
Summary of information on human CYP enzymes: human P450 metabolism data.
Drug Metab Rev. 2002 Feb-May;34(1-2):83-448
PMID: 11996015
-
An overview of the mechanism, substrate specificities, and structure of FMOs.
Drug Metab Rev. 2002 Aug;34(3):503-11
PMID: 12214662
-
Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis.
Mutat Res. 2002 Sep 30;506-507:65-77
PMID: 12351146
-
Genetic contribution to variable human CYP3A-mediated metabolism.
Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94
PMID: 12406645
-
Cancer and phase II drug-metabolizing enzymes.
Curr Drug Metab. 2003 Feb;4(1):45-58
PMID: 12570745
-
Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.
Pharmacogenetics. 2003 Mar;13(3):173-81
PMID: 12618595
-
Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Drug Metab Dispos. 2003 May;31(5):548-58
PMID: 12695342
-
P450 structures and oxidative metabolism of xenobiotics.
Pharmacogenomics. 2003 Jul;4(4):387-95
PMID: 12831319
-
Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants.
Pharmacogenetics. 2004 Jan;14(1):1-18
PMID: 15128046
-
Polymorphic hydroxylation of Debrisoquine in man.
Lancet. 1977 Sep 17;2(8038):584-6
PMID: 71400
-
The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.
Am J Hum Genet. 1989 Dec;45(6):889-904
PMID: 2574001
-
Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation.
Trends Genet. 1990 Jun;6(6):182-6
PMID: 2196721
-
Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.
J Pharmacol Exp Ther. 1994 Oct;271(1):549-56
PMID: 7965755
-
An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials.
Toxicol Pathol. 1996 Jan-Feb;24(1):48-57
PMID: 8839280